OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Early cervical cancer and fertility-sparing surgery: the decisions you may face

6 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Stage IA1 without lymphovascular invasion

One path named

Cone biopsy with clear margins or simple hysterectomy; no node assessment needed.

The path, in plain words

Looking at the cervix with a magnifier after a positive screen, then removing the abnormal patch with an electric wire loop in a clinic visit.

  • Outpatient, definitive histology
  • High cure rate
Also referenced:Hysterectomy
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Requires trained providers and equipment
  • Obstetric risk after excision
Questions to ask about this decision
  1. Is Colposcopy and excisional treatment (LEEP/LLETZ, cone) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. For my situation (stage ia1 without lymphovascular invasion), which of the standard options do you recommend and why?
    Why: Guideline options include: Cone biopsy with clear margins or simple hysterectomy; no node assessment needed.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Stage IA2 to IB1 up to 2 cm, low risk

2 options

Simple hysterectomy with node assessment (SHAPE) or open radical hysterectomy; sentinel node biopsy where a trial or protocol supports it.

The options, in plain words

Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.

  • Avoids lymphoedema from full dissection
MRIStandard of care

MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.

  • No ionising radiation
  • Best soft-tissue and brain imaging
  • Functional sequences (diffusion, perfusion)
Also referenced:Hysterectomy
The evidence behind it
The main trade-offs on record
  • False negatives in ~5-10%
  • Slow and expensive
  • Motion artefacts
  • Gadolinium concerns in renal impairment
Questions to ask about this decision
  1. Between Sentinel lymph node biopsy and MRI, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in SENTICOL III, and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  5. For my situation (stage ia2 to ib1 up to 2 cm, low risk), which of the standard options do you recommend and why?
    Why: Guideline options include: Simple hysterectomy with node assessment (SHAPE) or open radical hysterectomy; sentinel node biopsy where a trial or protocol supports it.
  6. How do the results of SENTICOL III apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Stage IB1 to IB2, standard

One path named

Open radical hysterectomy with pelvic lymphadenectomy; minimally invasive radical hysterectomy avoided after LACC.

The path, in plain words

Surgeons operate through small incisions using robotic arms with tremor-free precision and 3D vision.

  • Precision, shorter stay
  • Enables complex minimally invasive resections
The evidence behind it
  • Early-stage cervical cancer (IA1 with LVSI to IB1): minimally invasive vs open radical hysterectomy
    Show survival figures (1)

    Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.

    • 4.5-year DFS 86.0% vs 96.5%; death HR 6.00 with MIS.
    Disease-free survival at 4.5 years (%): Minimally invasive 86 (n=319) vs Open surgery 96.5 (n=312) · HR 3.74 · source
The main trade-offs on record
  • Cost
  • Loss of haptic feedback
  • Not superior for every indication
Questions to ask about this decision
  1. Is Robotic & minimally invasive surgery the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in LACC (Laparoscopic Approach to Cervical Cancer), and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  5. For my situation (stage ib1 to ib2, standard), which of the standard options do you recommend and why?
    Why: Guideline options include: Open radical hysterectomy with pelvic lymphadenectomy; minimally invasive radical hysterectomy avoided after LACC.
  6. How do the results of LACC (Laparoscopic Approach to Cervical Cancer) apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Special situations

Fertility preservation

3 options

Cone or simple trachelectomy for IA disease; radical trachelectomy with node assessment for IB1 tumours up to 2 cm.

The options, in plain words

Looking at the cervix with a magnifier after a positive screen, then removing the abnormal patch with an electric wire loop in a clinic visit.

  • Outpatient, definitive histology
  • High cure rate

Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.

  • Avoids lymphoedema from full dissection
MRIStandard of care

MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.

  • No ionising radiation
  • Best soft-tissue and brain imaging
  • Functional sequences (diffusion, perfusion)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Requires trained providers and equipment
  • Obstetric risk after excision
  • False negatives in ~5-10%
  • Slow and expensive
  • Motion artefacts
  • Gadolinium concerns in renal impairment
Questions to ask about this decision
  1. Between Colposcopy and excisional treatment (LEEP/LLETZ, cone), Sentinel lymph node biopsy and MRI, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. For my situation (fertility preservation), which of the standard options do you recommend and why?
    Why: Guideline options include: Cone or simple trachelectomy for IA disease; radical trachelectomy with node assessment for IB1 tumours up to 2 cm.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Adjuvant after surgery

3 options

Pelvic radiotherapy for intermediate-risk features; cisplatin chemoradiation for positive nodes, margins or parametria.

The options, in plain words

IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.

  • Conformal dose, fewer side effects
  • Hypofractionation saves visits

Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.

BrachytherapyStandard of care

Brachytherapy places a radioactive source directly inside or next to the tumour.

  • Highest conformality
  • Short treatment
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Low-dose bath to normal tissue
  • Motion management
  • Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).
  • Invasive
  • Declining expertise in some regions
Questions to ask about this decision
  1. Between IMRT / IGRT (modern external beam), Cisplatin and Brachytherapy, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. For my situation (adjuvant after surgery), which of the standard options do you recommend and why?
    Why: Guideline options include: Pelvic radiotherapy for intermediate-risk features; cisplatin chemoradiation for positive nodes, margins or parametria.
  5. Am I a candidate for Cisplatin, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Screening, prevention and diagnosis

Prevention and detection

3 options

HPV vaccination and HPV-based screening with colposcopy for positives.

The options, in plain words
HPV & HBV vaccinationStandard of care

Vaccines that prevent the viral infections behind cervical, throat, anal, and liver cancers. The most effective anti-cancer intervention ever created.

  • Prevents cancer outright
  • Cheap at scale

A swab tested for the virus that causes cervical cancer, more accurate than the Pap smear and doable at home.

  • Higher sensitivity for precancer than cytology
  • Self-sampling reaches never-screened women
  • Long safe intervals cut cost

Looking at the cervix with a magnifier after a positive screen, then removing the abnormal patch with an electric wire loop in a clinic visit.

  • Outpatient, definitive histology
  • High cure rate
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
  • Coverage gaps, vaccine hesitancy
  • Lower specificity in young women (transient infection)
  • Needs triage (cytology, genotyping, methylation) before colposcopy
  • Requires trained providers and equipment
  • Obstetric risk after excision
Questions to ask about this decision
  1. Between HPV & HBV vaccination, HPV DNA testing and self-sampling and Colposcopy and excisional treatment (LEEP/LLETZ, cone), which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. For my situation (prevention and detection), which of the standard options do you recommend and why?
    Why: Guideline options include: HPV vaccination and HPV-based screening with colposcopy for positives.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.